epitalon is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-07-06. Numbers and descriptions here follow the published literature rather than marketing material.
Published work on this compound consists mainly of in vitro experiments, animal studies, and small clinical investigations, a substantial share of which appeared in Russian-language journals. Sample sizes are generally small, control conditions differ between studies, and several endpoints rely on markers whose clinical meaning is itself debated. Reviews of the longevity field treat the peptide as an early example of telomerase-directed research rather than an established intervention. Regulatory treatment varies by country: some jurisdictions place it under prescription controls, others treat it as a laboratory material, and importation may be restricted regardless of local status.
Epitalon is a synthetic tetrapeptide whose sequence is alanine–glutamate–aspartate–glycine, commonly abbreviated AEDG. It was developed in Russia during the 1980s and 1990s by investigators associated with the St. Petersburg Institute of Bioregulation and Gerontology, who studied short peptides as regulators of gene expression and tissue function. The alternative spelling epithalon appears interchangeably in the literature, and the two names refer to the same molecule. Outside Russia it is encountered chiefly as a research chemical rather than a licensed medicine, and it holds no approval from the United States Food and Drug Administration or the European Medicines Agency.
The peptide is a synthetic analogue of epithalamin, a preparation extracted from bovine pineal glands. Investigators sought a short, chemically defined molecule that would reproduce some of the endocrine and gerontological observations attributed to the glandular extract. Proposed mechanisms centre on induction of telomerase activity, an effect reported in cultured human somatic cells in the early 2000s, together with influences on melatonin secretion and neuroendocrine regulation. Those mechanisms remain incompletely characterised, and the reported telomerase response has not been consistently reproduced by independent groups working in comparable systems.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography with ultraviolet detection, frequently near 214 nanometers where the peptide bond absorbs. Mass spectrometry, most often with electrospray ionization, confirms the observed molecular mass and helps separate the intact peptide from truncated or modified forms. Amino acid analysis or tandem mass spectrometry can establish residue order. Purity is commonly quoted as an area percentage, yet such values are method-dependent, and comparisons between laboratories require matching column, gradient and detection wavelength.
Laboratory handling begins with dissolution of the lyophilized powder in water or a suitable aqueous buffer. The dry solid is the more stable form, so stock solutions are generally prepared only when required and kept cold afterwards. Repeated freezing and thawing of a solution is avoided because it encourages aggregation and gradual loss of the intact chain. Diluents and containers are selected to limit adsorption of a short peptide onto plastic surfaces and to reduce microbial growth in aqueous preparations.
| Property | Value | Notes |
|---|---|---|
| Peptide sequence | Ala-Glu-Asp-Gly | Often abbreviated AEDG in research literature |
| Common synonyms | Epithalon, epitalon, AEDG | Spelling variants refer to the same tetrapeptide |
| Molecular formula | C14H22N4O9 | Theoretical monoisotopic mass near 390.35 Da |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility class | Freely soluble in water | Hydrophilic peptide; dissolves in aqueous buffer |
Reported biological findings come mainly from cell culture and rodent experiments. Those studies describe changes in telomerase catalytic subunit expression, melatonin rhythm amplitude, and antioxidant enzyme activity after peptide exposure. Human data are sparse and consist of small trials with limited blinding and inconsistent endpoints. The proposed mechanisms remain hypotheses rather than established facts, and there is no consensus on whether effects observed in animals carry over to people. Independent replication outside the original research groups is limited, which is a recognised gap in the published literature.
The parent extract epithalamin was characterised as a low-molecular-weight fraction of pineal tissue rather than a single defined chemical entity. Researchers fractionated it and tested successive fragments for activity, a screening approach typical of peptide discovery work in that era. Epitalon emerged from that process as one of the shorter sequences of interest. Because the original extract was never fully resolved into individual components, claims about which constituent drives a given effect rest on inference. This distinction matters when reading older reports that attribute extract observations to the tetrapeptide itself.
Epitalon is a synthetic tetrapeptide with the residue sequence alanine-glutamate-aspartate-glycine, commonly abbreviated AEDG. Its monoisotopic mass is approximately 390.35 daltons, and it is usually supplied as a lyophilised trifluoroacetate or acetate salt. The compound was derived from a pineal gland extract called epithalamin, a heterogeneous preparation investigated in the former Soviet Union. Researchers associated with the Saint Petersburg Institute of Bioregulation and Gerontology described the tetrapeptide as a constituent fragment of that extract. Commercial material is offered as a laboratory reagent rather than as a finished pharmaceutical product.
Because epitalon has no pharmacopoeial monograph, quality assessment depends on supplier documentation and independent testing. Certificates of analysis typically report a purity figure from a single chromatographic run, a measured mass and sometimes an appearance description, but methods and acceptance criteria are not harmonised across vendors. Third-party laboratories can repeat identity and purity measurements, and mismatches between labelled and measured peptide content have been described for research peptides generally. What constitutes adequate identity confirmation for a molecule of this size stays an open question, since mass agreement alone does not separate closely related sequences.
Identity testing for epitalon relies on reversed-phase high-performance liquid chromatography for purity and mass spectrometry for mass confirmation. Because the sequence contains no tryptophan or tyrosine, ultraviolet detection at 280 nanometres is insensitive, so chromatographic methods usually monitor absorbance near 214 nanometres, where the peptide backbone absorbs. Electrospray ionisation or matrix-assisted laser desorption/ionisation then checks the intact mass against the expected value near 390 daltons. Peptide mapping or amino acid analysis after acid hydrolysis can supplement these measurements, although such confirmatory work is seldom reported on commercial certificates of analysis.
=== Other psychoactive effects === Some psychedelics have been associated with other psychoactive effects in addition to their hallucinogenic effects. For example, psychedelics like LSD and DOM have been described as having mild stimulant and/or "psychic-energizing" (i.e., acute antidepressant) effects. Some psychedelics and related drugs, like DOET (low doses), Ariadne, and ASR-2001 (2CB-5PrO), have been investigated specifically for such effects. 2C-B has been said to have mild entactogenic effects at low doses. 5-MeO-DiPT and 5-MeO-MiPT have unique and unusual effects at typical doses including tactile and sexual enhancement, mild entactogenic effects, and only light hallucinogenic effects. Uniquely among psychedelics, LSD shows biphasic effects and two temporally distinct phases of effects, including an initial psychedelic state and a delayed "paranoid" or psychosis-like state. LSD's delayed second phase of effects is associated with dopamine D2-like receptor agonism, most likely due to the highly potent dopamine D4 receptor agonism of its metabolite 13-hydroxy-LSD. Some drugs, such as MDxx compounds like MDMA and MDA as well as α-alkyltryptamines like α-methyltryptamine (AMT), are entactogens and/or stimulants acting at monoamine transporters in addition to having varying degrees of psychedelic effects.
Part of the WADA submission to the appeal, which the CAS accepted in its verdict, was that Thymosin Beta-4 was the only form of Thymosin which would have had the soft tissue recovery effect that Dank had attributed to it – text messages from Dank had specifically described Thymosin as the cornerstone of the soft tissue recovery program. Two urine samples taken from Essendon players during 2012 were also found to contain elevated Thymosin Beta-4; the levels were not high enough to fail the drug test, but they added to the cable of evidence against the players. Significantly, the CAS also determined that the players were "significantly at fault", disqualifying them from any penalty reduction. This was considered a surprise, as press throughout the entire saga had opined that by having followed the direction of club officials, the players would be found to have had no significant fault or negligence, qualifying them for a 50% penalty reduction. Key to this finding was the revelation that none of the eighteen different players who had been drug tested on a total of thirty occasions during the program had declared the supplements injections on their doping control forms, and that some had withheld information from the club doctor on Dank's instruction – revelations which damaged the credibility of other evidence put forward by the players.
ketamine (K; Ketalar, Ketaset, Ketanest; "Ket", "Kit Kat", "Special-K", "Vitamin K", "Jet Fuel", "Horse Tranquilizer") methoxetamine (Mex, Mket, Mexi) phencyclidine (PCP; Sernyl; "Angel Dust", "Rocket Fuel", "Sherm", "Killer Weed", "Super Grass") nitrous oxide (N2O; "NOS", "Laughing Gas", "Whippets", "Balloons") Psychedelics Phenethylamines 2C-B ("Nexus", "Venus", "Eros", "Bees") 2C-E ("Eternity", "Hummingbird") 2C-I ("Infinity") 2C-T-2 ("Rosy") 2C-T-7 ("Blue Mystic", "Lucky 7") DOB DOC DOI DOM ("Serenity, Tranquility, and Peace" ("STP")) MDMA ("Ecstasy", "E", "Molly", "Mandy", "MD", "Crystal Love") mescaline (found in peyote and Trichocereus macrogonus (Peruvian torch, San Pedro cactus, Echinopsis langeniformis)) Tryptamines (including ergolines and lysergamides) 5-MeO-DiPT ("Foxy", "Foxy Methoxy") 5-MeO-DMT (found in various plants like chacruna, jurema, vilca, and yopo) α-methyltryptamine (αMT; Indopan; "Spirals") bufotenin (secreted by Bufo alvarius, also found in various Amanita mushrooms) dimethyltryptamine (DMT; "Dimitri", "Disneyland", "Spice"; found in large amounts in Psychotria and in D. cabrerana) lysergic acid amide (LSA; ergine; found in morning glory and Hawaiian baby woodrose seeds) lysergic acid diethylamide (LSD; L; Delysid; "Acid", "Sid".
A deuterated drug is a small molecule medicinal product in which one or more of the hydrogen atoms in the drug molecule have been replaced by deuterium. Because of the kinetic isotope effect, deuterium-containing drugs may have significantly lower rates of metabolism, and hence a longer half-life. In 2017, deutetrabenazine became the first deuterated drug to receive FDA approval.
== History == Transaid was founded in 1998 by Save the Children, the Chartered Institute of Logistics and Transport (CILT), and its patron, Anne, Princess Royal. It is a UK‑based international development charity focused on transforming lives through safe, available, and sustainable transport in sub‑Saharan Africa. The charity operates multiple programmes in several countries, working with governments, communities, and industry partners to improve road safety, transport management, and access to healthcare. In recent years, Transaid has been active in motorcycle helmet safety in Kenya through its Kenya National Helmet Wearing Coalition, working with the FIA Foundation and others to build enforcement of helmet standards, establish awareness among riders, and to set up a helmet testing laboratory in East Africa. The charity has also launched its Christmas Appeal 2025 to raise funds from individuals and businesses for road safety and healthcare access across sub‑Saharan Africa; in that appeal, it reported having trained over 9,000 professional drivers and riders, delivered thousands of eye tests, and supported minibus‑taxis adopting safety charters. Additionally in early 2025, Princess Anne opened the new London office of Arbuthnot Latham, a corporate partner of Transaid, emphasising the strengthening of corporate backing and visibility for the charity.
Sources: en.wikipedia.org
They compare the audience's early ridicule of Viserys' struggles to Daemon's own reactions, as the fierce Daemon attempts to distinguish himself from the "weak" Viserys due to his own abjection, while several audience members laughed at a scene in "We Light the Way" where Viserys struggles to cut his food as a result of losing his fingers. Heath notes that this "mutual distaste or disappointment evaporates" when a frail Viserys walks toward the Iron Throne in "The Lord of the Tides", as Daemon "shows care and even reverence to his brother" while the audience is touched by Viserys' heroic perseverance instead of joking about his condition.
=== Total Hip Arthroplasty for DDH in the Adult === A clinical research based on Xrays and Computed Tomography aimed at establishing an algorithm of the challenging surgical technique in a condition with distorted anatomy of the hip joint. The system served for self-assessment of Orthopedic Surgeons in the USA.
Dean Ho is a Provost's Chair Professor in the Departments of Biomedical Engineering and Pharmacology, Director of the N.1 Institute for Health, Director of the Institute for Digital Medicine, and Head of the Department of Biomedical Engineering at the National University of Singapore. He was previously a professor at UCLA, and associate professor in the Departments of Biomedical Engineering and Mechanical Engineering in the Robert R. McCormick School of Engineering and Applied Science, and Full Member of the Robert H. Lurie Comprehensive Cancer Center at the Feinberg School of Medicine of Northwestern University, Illinois, United States.
==== Immunotherapy ==== Immunotherapy successfully treats some kinds of cancer, such as melanoma. This treatment involves manipulating a human's immune system to destroy cancerous cells. Humans have two major antigen identifying lymphocytes: CD8+ cytotoxic T-lymphocytes (CTL) and CD4+ helper T-lymphocytes that can destroy cells. Antigen receptors on CTL can bind to a 9–10 amino acid chain that is presented by the major histocompatibility complex (MHC) as in Figure 4. HTERT is a potential target antigen. Immunotargeting should result in relatively few side effects since hTERT expression is associated only with telomerase and is not essential in almost all somatic cells. GV1001 uses this pathway. Experimental drug and vaccine therapies targeting active telomerase have been tested in mouse models, and clinical trials have begun. One drug, imetelstat, is being clinically researched as a means of interfering with telomerase in cancer cells. Most of the harmful cancer-related effects of telomerase are dependent on an intact RNA template. Cancer stem cells that use an alternative method of telomere maintenance are still killed when telomerase's RNA template is blocked or damaged.
Sources: en.wikipedia.org
The NRD pathway for the 40S subunit may be independent or separate from the NRD pathway for the 60S subunit. It has been observed that certain genes were able to affect degradation of certain pre-RNAs, but not others. Numerous proteins are involved in the NRD pathway, such as Mms1p and Rtt101p, which are believed to complex together to target ribosomes for degradation. Mms1p and Rtt101p are found to bind together and Rtt101p is believed to recruit a ubiquitin E3 ligase complex, allowing for the non-functional ribosomes to be ubiquinated before being degraded. Prokaryotes lack a homolog for Mms1, so it is unclear how prokaryotes are able to degrade non-functional rRNAs. The growth rate of eukaryotic cells did not seem to be significantly affected by the accumulation of non-functional rRNAs.
== Research == (R)-MDMA is under development separately by AtaiBeckley, Empath Biosciences (EmpathBio) and Definium Therapeutics (formerly MindMed). It is being developed by AtaiBeckley for social anxiety disorder, by Empath Biosciences for the treatment of PTSD and social phobia and it is being developed by Definium Therapeutics for the treatment of PDDs or autism. As of February 2026, the drug is in phase 2 clinical trials for social phobia and autistic spectrum disorders, whereas no recent development has been reported for PTSD. The results of AtaiBeckley's phase 2a trial for treatment of social phobia have been released, with the drug showing moderate effectiveness and a generally favorable safety profile for this indication.
== Contraindications == Like other dihydropyridines, lercanidipine is contraindicated in unstable angina pectoris, uncontrolled cardiac failure, shortly after a myocardial infarction, and in patients with left ventricular outflow tract obstruction. It is also contraindicated during pregnancy and in women who may become pregnant, because data regarding safety for the unborn are lacking, as well as in patients with severe liver and renal impairment. The drug must not be combined with strong inhibitors of the liver enzyme CYP3A4 or with the immunosuppressant drug ciclosporin.
== Nomenclature == Accepted nomenclature is to designate the number of components of the rotaxane in brackets as a prefix. Therefore, the rotaxane consisting of a single dumbbell-shaped axial molecule with a single macrocycle around its shaft is called a [2]rotaxane, and two cyanostar molecules around the central phosphate group of dialkylphosphate is a [3]rotaxane.
Mephedrone administration leads to increased extracellular dopamine in the nucleus accumbens, elevated serotonin levels in the frontal cortex, and alterations in brain temperature. These pharmacodynamic actions translate into various behavioral effects, including increased locomotor activity, rewarding effects (as measured by conditioned place preference), and potential for drug discrimination (similar to cocaine and MDMA).
Sources: en.wikipedia.org
Epitalon is a synthetic four-amino-acid peptide with the sequence alanine–glutamate–aspartate–glycine, also written AEDG. It was developed in Russian gerontology research and is studied for proposed effects on telomerase, melatonin regulation, and neuroendocrine function. It is not an approved pharmaceutical in the United States or the European Union.
No. Epithalamin is a peptide-rich extract prepared from bovine pineal glands, while epitalon is a short synthetic peptide designed as a defined analogue of it. The synthetic version was intended to provide a reproducible molecule with some of the same proposed biological activity.
Telomere elongation and telomerase activation have been reported in cultured human somatic cells, but evidence from living human subjects is limited and has not been independently confirmed at scale. Reported findings come largely from small studies with differing designs, so the question remains open rather than settled.
The dry powder is typically held at -20 degrees Celsius or lower, protected from light and moisture. Allowing a sealed vial to reach room temperature before opening reduces condensation on its contents. Conditions stated on a supplier certificate of analysis take precedence over general guidance.